“Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®) for the treatment of late stage non-small cell lung cancer (NSCLC) patients.”
“Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways.
“The trial is significant in that it seeks to determine if patients without the EGFR activating mutation as well as patients with the EGFR activating mutation whose cancer has progressed after erlotinib treatment can benefit from the Oncoprex + erlotinib combination therapy. While erlotinib is a blockbuster drug helping many cancer patients worldwide, research shows that the vast majority of patients who have lung cancers without the activating EGFR mutation are unlikely to benefit from erlotinib. Additionally, many patients with the activating EGFR mutation who respond to erlotinib therapy eventually become resistant to the therapy.“
Editor’s note: Clinical trials are studies done with volunteer patients to evaluate the safety and effectiveness of new treatments (learn more in our lung cancer KnowledgeBase). This clinical trial is testing a new targeted therapy drug called Oncoprex. When combined with the drug erlotinib (Tarceva), Oncoprex may help treat patients who usually do not benefit from erlotinib or who have grown resistant to it.